FDA product code KKH: Tablet, Resazurin
KKH is the FDA product code for tablet, resazurin. It is a Class I device, regulated under 21 CFR 864.1850 and reviewed by the Pathology panel. Devices under KKH reach the market by 510(k) exempt; FDA lists no cleared 510(k)s for it. FDA has posted 1 recall for KKH devices, 1 initiated in the last five years.
Classification
| Field | Value |
|---|---|
| Device name | Tablet, Resazurin |
| Device class | Class I |
| Regulation | 21 CFR 864.1850 |
| Review panel | PA — Pathology |
| Medical specialty | Hematology |
| Premarket route | 510(k) exempt |
| GMP exempt | Yes |
Recalls for KKH devices
1 product recalls in 1 recall events; 1 initiated in the last five years and 1 still open. Most recent: 2022-05-25.
| Year | Recalls |
|---|---|
| 2022 | 1 |
Frequently asked questions
What is FDA product code KKH?
KKH is the FDA product code for tablet, resazurin. It is a Class I device, regulated under 21 CFR 864.1850 and reviewed by the Pathology panel.
What device class is KKH?
Class I, regulation 21 CFR 864.1850. Typical premarket route: 510(k) exempt.
Have KKH devices been recalled?
Yes: 1 product recalls across 1 recall events; the most recent began 2022-05-25.
Next steps
- Run an FDA pathway report with predicate devices for product code KKH
- Run a recall and safety report across every KKH manufacturer
- Watch product code KKH for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Pathology product codes · FDA product code lookup · 510(k) database search · 510(k) review times